3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors

International Journal of Neuropsychopharmacology

Volumn 17, Issue 8, 2014, Pages 1243-1255

  Rubio Araiz, Ana ^a   Perez Hernandez, Mercedes ^a   Urrutia, Andrés ^a   Porcu, Francesca ^a   Borcel, Erika ^a   Gutierrez Lopez, Maria Dolores ^a   O'Shea, Esther ^a   Colado, Maria Isabel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Collagen IV; IgG; laminin; MDMA; P2X7R

Indexed keywords

3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; BRILLIANT BLUE G; COLLAGEN TYPE 4; GELATINASE B; IMMUNOGLOBULIN G; LAMININ; PURINERGIC P2X RECEPTOR; PURINERGIC P2X RECEPTOR ANTAGONIST; SCLEROPROTEIN; STROMELYSIN; UNCLASSIFIED DRUG; 3-(5-(2,3-DICHLOROPHENYL)-1H-TETRAZOL-1-YL)METHYLPYRIDINE; COOMASSIE BRILLIANT BLUE; FUCHSINE; PURINERGIC P2X RECEPTOR AGONIST; PURINERGIC P2X7 RECEPTOR; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CONTROLLED STUDY; DENTATE GYRUS; DRUG MECHANISM; ENZYME ACTIVITY; HIPPOCAMPUS; IMMUNOREACTIVITY; MALE; MICROGLIA; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY TEMPERATURE; DRUG EFFECTS; METABOLISM;

ANIMALS; BLOOD-BRAIN BARRIER; BODY TEMPERATURE; COLLAGEN TYPE IV; DENTATE GYRUS; HIPPOCAMPUS; IMMUNOGLOBULIN G; LAMININ; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MICROGLIA; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PURINERGIC P2X RECEPTOR AGONISTS; PURINERGIC P2X RECEPTOR ANTAGONISTS; PYRIDINES; RATS; RECEPTORS, PURINERGIC P2X7; ROSANILINE DYES; TETRAZOLES;

EID: 84927566461     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145714000145     Document Type: Article

References (54)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37:13-25.
2. Bianco F, Pravettoni E, Colombo A, Schenk U, Möller T, Matteoli M, Verderio C (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174:7268-7277.
3. Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87:659-797.
4. Chakfe Y, Seguin R, Antel JP, Morissette C, Malo D, Henderson D, Séguéla P (2002) ADP and AMP induce interleukin-1beta release from microglial cells through activation of ATP-primed P2X7 receptor channels. J Neurosci 22:3061-3069.
5. Choi HB, Ryu JK, Kim SU, McLarnon JG (2007) Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharidemediated microglial activation and neuronal damage in inflamed brain. J Neurosci 27:4957-4968.
6. Cisneros IE, Ghorpade A (2012) HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for Neuro-AIDS. Current HIV Research 10:392-406.
7. Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB, Malcangio M (2010) P2X7-dependent release of interleukin-1 beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci 30:573-582.
8. Colado MI, O'Shea E, Granados R, Murray TK, Green AR (1997a) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121:889-900.
9. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR (1997b) A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827-833.
10. Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G (1997) Tissue distribution of the P2X7 receptor. Neuropharmacology 36:1277-1283.
11. Díaz-Hernández M, Díez-Zaera M, Sánchez-Nogueiro J, Gómez-Villafuertes R, Canals JM, Alberch J, Miras-Portugal MT, Lucas JJ (2009) Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J 23:1893-1906.
12. Dunn M, Day C, Bruno R, Degenhardt L, Campbell G (2010) Sexual and injecting risk behaviours among regular ecstasy users. Addict Behav 35:157-160.
13. Engel T, Jimenez-Pacheco A, Miras-Portugal MT, Diaz-Hernandez M, Henshall DC (2012) P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control. Int J Physiol Pathophysiol Pharmacol 4:174-187.
14. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH (2001) Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21:1393-1400.
15. Grygorowicz T, Struzynska L, Sulkowski G, Chalimoniuk M, Sulejczak D (2010) Temporal expression of P2X7 purinergic receptor during the course of experimental autoimmune encephalomyelitis. Neurochem Int 57:823-829.
16. Gottschall PE, Deb S (1996) Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 3:69-75.
17. Gurney KJ, Estrada EY, Rosenberg GA (2006) Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 23:87-96.
18. Jiang LH, Mackenzie AB, North RA, Surprenant A (2000) Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 58:82-88.
19. Jo S, Bean BP (2011) Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol Pharmacol 80:247-257.
20. Katsu M, Niizuma K, Yoshioka H, Okami N, Sakata H, Chan PH (2010) Hemoglobin-induced oxidative stress contributes to matrix metalloproteinase activation and blood-brain barrier dysfunction in vivo. J Cereb Blood Flow Metab 30:1939-1950.
21. Kim EM, Hwang O (2011) Role of matrix metalloproteinase-3 in neurodegeneration. J Neurochem 116:22-32.
22. Kimbler DE, Shields J, Yanasak N, Vender JR, Dhandapani KM (2012) Activation of P2X7 promotes cerebral edema and neurological injury after traumatic brain injury in mice. PLoS ONE 7:e41229.
23. Klein H, Elifson KW, Sterk CE (2010) Self-esteem and HIV risk practices among young adult ecstasy users. J Psychoactive Drugs 42:447-456.
24. Lee HG, Won SM, Gwag BJ, Lee YB (2011) Microglial P2X7 receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer's disease. Exp Mol Med 43:7-14.
25. Lee JY, Kim HS, Choi HY, Oh TH, Yune TY (2012) Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury. Brain 135:2375-2389.
26. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, Wang YJ, Zhou L, Ho WZ (2008) Methamphetamine Enhances HIV Infection of macrophages. Am J Pathol 172:1617-1624.
27. Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124:1743-1753.
28. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, Finlayson K (2007) The role of the purinergic P2X7 receptor in inflammation. J Inflamm 4:5.
29. Liu KJ, Rosenberg GA (2005) Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 39:71-80.
30. Marcellino D, Suárez-Boomgaard D, Sánchez-Reina MD, Aguirre JA, Yoshitake T, Yoshitake S, Hagman B, Kehr J, Agnati LF, Fuxe K, Rivera A (2010) On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079. J Neural Transm 117:681-687.
31. Melani A, Amadio S, Gianfriddo M, Vannucchi MG, Volontè C, Bernardi G, Pedata F, Sancesario G (2006) P2X7 receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. J Cereb Blood Flow Metab 26:974-982.
32. Monif M, Reid CA, Powell KL, Smart ML, Williams DA (2009) The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci 29:3781-3791.
33. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, González MA, Monasterio J (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759-1766.
34. Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, Niforatos W, Honore P, Jarvis MF, Faltynek CR, Carroll WA (2006) Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem 49:3659-3666.
35. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, Colado MI (2004) 3,4-Methylenedioxymethamphetamine increases interleukin-1 beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89:1445-1453.
36. Orio L, Llopis N, Torres E, Izco M, O'Shea E, Colado MI (2010) A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons. Neurotox Res 18:187-199.
37. Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L, Takano T, Tian GF, Goldman SA, Nedergaard M (2009) Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 106:12489-12493.
38. Ramos-De Simone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076.
39. Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, Grüterich M, Priglinger SG, Nentwich MM, Kampik A, Haritoglou C (2008) An in vivo evaluation of Brilliant Blue G in animals and humans. Br J Ophtalmol 92:1142-1147.
40. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8:205-216.
41. Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK (2007) Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood-brain barrier permeability without overt neurodegeneration. J Neurosci 27:9301-9309.
42. Sharma HS, Ali SF (2008) Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, blood-brain barrier disruption, brain edema formation, and cell injury. Ann N Y Acad Sci 1139:242-258.
43. Sim JA, Young MT, Sung HY, North RA, Surprenant A (2004) Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci 24:6307-6314.
44. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA (2001) Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276:125-132.
45. Tian W, Kyriakides TR (2009) Matrix metalloproteinase-9 deficiency leads to prolonged foreign body response in the brain associated with increased IL-1ß levels and leakage of the blood brain barrier. Matrix Biol 28:148-159.
46. Torres E, Gutierrez-Lopez MD, Borcel E, Peraile I, Mayado A, O'Shea E, Colado MI (2010) Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. J Neurochem 113:67-78.
47. Torres E, Gutierrez-Lopez MD, Mayado A, Rubio A, O'Shea E, Colado MI (2011) Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity. J Neuroinflammation 8:53.
48. Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10:210-215.
49. Urrutia A, Rubio-Araiz A, Gutierrez-Lopez MD, ElAli A, Hermann DM, O'Shea E, Colado MI (2013) A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine. Neurobiol Dis 50:49-58.
50. Vecil GG, Larsen PH, Corley SM, Herx LM, Besson A, Goodyer CG, Yong VW (2000) Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res 61:212-224.
51. Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM (2011) Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 31:52-57.
52. Weber E, Morgan EE, Iudicello JE, Blackstone K, Grant I, Ellis RJ, Letendre SL, Little S, Morris S, Smith DM, Moore DJ, Woods SP; TMARC Group (2013) Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol 19:65-74.
53. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6:12.
54. Zhou J, Li J, Rosenbaum DM, Barone FC (2011) Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury. J Cereb Blood Flow Metab 31:924-933.